Squamous Cell Lung Cancer: Where Do We Stand and Where Are We Going?
September 16th 2013The Cancer Genome Atlas results have led to some encouraging advances in the clinical perspective on squamous cell lung cancer and spurred new initiatives targeting patients with squamous cell lung cancer, giving us hope for future improvements in clinical management and therapeutic outcomes for this subgroup of lung cancer patients.
Developing CT Image-Processing Tools to Accelerate Progress in Lung Cancer Drug Development
November 1st 2006On April 21, 2005, the Cancer Research and Prevention Foundation (CRPF), in conjunction with academic researchers, federal scientists, lung cancer advocates, and representatives of a number of pharmaceutical and diagnostic imaging companies, participated in a workshop held in Annapolis, Md, on the development of high-resolution spiral computed tomography (CT) imaging tools to assess therapeutic response in lung cancer clinical trials. In this report, we will address developments that led up to that workshop, what was discussed, and recommendations that came out of the meeting.
Commentary (Dziadziuszko/Hirsch): EGFR Inhibitors in Lung Cancer
November 1st 2005Inhibitors targeting the family ofepidermal growth factor receptors(EGFRs) are novel antitumor compoundsinvestigated in many cancertypes, including non–small-cell lungcancer (NSCLC). In this special lungcancer issue of ONCOLOGY, Drs.Buter and Giaccone provide us withan updated review of clinical researchon two classes of these agents inNSCLC: small-molecule tyrosinekinase inhibitors (TKIs) and monoclonalantibodies. The former classincludes gefitinib (Iressa) and erlotinib(Tarceva), two orally availablequinazoline derivatives targeting thetyrosine kinase domain of EGFR. Thelatter includes cetuximab (Erbitux), achimeric monoclonal antibody directedagainst EGFR. The authors extensivelydiscuss single-agent andcombination activities of these drugsin NSCLC.